changing the way the world breathes€¦ · mr ron dewhurst - chairman mr michael johnson – ceo...

© RHINOMED LTD 2015 COMMERICAL IN CONFIDENCE WWW.RHINOMED.GLOBAL© RHINOMED LTD 2015 WWW.RHINOMED.GLOBAL

CHANGING THE WAY THE WORLD BREATHES

© RHINOMED LTD 2015 WWW.RHINOMED.GLOBAL

R H I N O M E D - N A S A L R E S P I R A T O R Y T E C H N O L O G Y

MASTER INVESTOR APRIL 2016


This document contains certain forward-looking statements , relating to Rhinomed Limited’s (Rhinomed) business which can be identified by the use of forward lookingterminology such as “promising”, “plans”, “anticipated” “will,” “project,” “believe,” “forecast”, “expected,” “estimated”, “targeting,” “aiming”, “set to”, “potential,” “seekingto”, “goal”, “could provide,” “intends”, “is being developed”, “could be ,” “on track” or similar expressions or by express or implied discussions regarding potential f ilings ormarketing approvals, or potentia l future sales of the company’s technologies and products. Such forward- looking statements involve known and unknown risks, uncertaintiesand other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.

There can be no assurance that any exis ting or future regulatory filings will satisfy any specific health authority and other health authorities requirements regarding any oneormore product or technology nor can there any assurance that such products or technologies will be approved by any health authorities for sale in any markets or that theywill reach any particular level of sales. In particular,managements expecta tions regarding the approval and commercialization of the technology could be affected by, amongother things, unexpected clinical trial results, including additiona l analysis of exis ting clinical da ta, and new clinical data; unexpected regulatory actions or delays, orgovernment regula tion genera lly; our ability to obtain ormaintain patent or other proprietary inte llectual property protection; competition in general; government, industry,and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, technology, f inancial result, and businessprospects.

Should one of more of these risks or uncertainties materialize , or should underlying assumptions prove incorrect, actual results may vary materially from those describedherein as anticipated, believed, estimated or expected. Rhinomed Is providing this information as of the date of this presentation and does not assume any obligation toupdate any forward –looking statements contained in this document as a result of new information, future events or developments or otherwise.

Disclaimer


P U R S U I N G A S I G N I F I C A N T G L O B A L O P P O R T U N I T Y

Rhinomedisamplifyingthebeliefthatbetterbreathingcanradicallyimprovehowyouperform,

recover,sleepandmaintainyourhealthbycreatingtheworld’smostelegant,innovativeand

clinicallybackednasalrespiratorytechnology.

Wepartnerwiththeworld’sbestandbrightestpeopletomakethisareality.


W H O I S R H I N O M E D ?

ASX:RNOEarly stagemedical technology company CashonHand~ 4.0Million

Offices:Melbourne,Australia andCincinnati, USA Revenues FYYTD – AU$750k

SharePrice~AU$0.024 Staff 11

MarketCap~AU$17million 60+patents,13granted plusadditional57designpatents

Globally experiencedboardandmanagementteam

Mr RonDewhurst - Chairman Mr Michael Johnson– CEOandManagingDirector

Mr Brent Scrimshaw- NonExec Director Ms Justineheath - CFO

Dr Eric Knight- NonExec Director Mr ShaneDuncan– HeadAmericas


Preclinical Phase 1 Regulatory In Market

TURBINE 2.0 OTC Dyspnea in Sport and Exercise

• FDA• TGA

• CANADA HEALTH• CE Mark

Preclinical User Trial

MUTE 1.0OTC Snoring and Sleep Quality

• FDA• TGA

• CANADA HEALTH• CE Mark

Congestion - OTC

Hayfever - OTC

Anxiety - OTC

Preclinical Phase 1 Phase 2 Phase 3 Regulatory In Market

Sleep Apnea

Drug Delivery – Acute Migraine (sumatriptan)

Seeking to partner

A N O V E L N A S A L T E C H N O L O G Y P L A T F O R M

© RHINOMED LTD 2015


T U R B I N E – S P O R T B R E A T H I N G T E C H N O L O G Y

• TURBINE2.0- Released Feb2015

• Designed tohelpathletes breatheeasier duringsportandaerobicexercise andhelpsthosesufferingfromnasal

obstruction

• Nowdistributedglobally

• Available inthree sizesandatrialpack

• RRPUS$27.95delivering strongmargins



TurbinehelpedChrisFroome winhissecondTourdeFrance


TurbinehelpedShannonRowbury setanewAmericanrecordforthe1500meters


S L E E P I S A M A J O R E M E R G I N G M A R K E T

Apple includedanew ‘bluelightfunctionintheirnewiphone OS release inMarch‘16

HuffingtonPostfounderAriannaHuffingtonistakingtheUSbystorm

Sleep isbeingpickedupmainstreammedia as a‘healthstory’


© RHINOMED LTD 2015 COMMERICAL IN CONFIDENCE

M U T E - C A T E G O R Y D E F I N I N G B R A N D E D T E C H N O L O G Y

• Mutereleased January2015

• Frontline therapy– Snoringandsleep quality

• Available inthree sizesandatrialpack

• RRP£$16.99– delivering strongmargins

• 1pack=1monthssupply(10usesper individualunit)


M U T E W O R K S – U S E R P R O D U C T T R I A L R E S U L T S

100

100

100

100

100

78%

73%

65%

67%

63%

78%IMPROVEMENT IN BREATHING ATNIGHT

73%REDUCTION IN SNORING SEVERITY

65%REDUCTION IN SNORING DURATION

67%REDUCTION IN SNORING VOLUME

63%REDUCTION IN SNORING FREQUENCY

MuteUser trial.N=236. 5Dayin-homeuser trial.November 2014


R H I N O M E D H A S A U N I Q U E , C U T T H R O U G H B R A N D


C U S T O M E R S L O V E M U T E


SPECIALISTS

GP’S

SLEEPCLINICS

DENTISTS

HOSPITALS

ONLINE

RETAILCHANNEL

ENTSURGEONS

GLOBAL RETAIL PHARMACY

CHANNEL DEPLOYMENT

A M U L T I - C H A N N E L D E P L O Y M E N T M O D E L


Launched Australia300Pharmacies

UKNov600Pharmacies

NOWTARGETING– 15,000+retailstoresgloballybyendCY17• 2000Pharmacies inAustralia andNew Zealand• 1200Pharmacies inUK• 1200Pharmacies inCanada• 2500Pharmacies inEurope• 15,000Pharmacies inUSA

2015 2016 2017

AppointCanadianDistributor

AppointAmericanSportsDistributor

USLaunchMay1000pharmacies

R A P I D L Y E X P A N D I N G G L O B A L D I S T R U B U T I O N


I N N O V A T I O N P I P E L I N E


E N D T O E N D S L E E P C A T E G O R Y S O L U T I O N S

SNORING

ON MARKET

CU

STO

MER

PAT

IEN

T N

UM

BER

MUTE 'CLEAR'Aroma enhanced

(menthol, eucalypt, sleep & relaxation

blends)

NASAL CONGESTION

MILD/MODERATE SLEEP APNEA

SEVERESLEEP APNEA

NAS

AL P

LATF

ORM

RNO INPEAPClinical trials (Reporting

first half 2016)

RNO ASPIRECombination Adjunct

Therapy

RNO + CPAP MaskRNO + Mandibular Splint



N E X T G E N E R A T I O N N A S A L D E C O N G E S T A N T



U S $ 8 B I L L I O N D E C O N G E S T I O N M A R K E T

MUTE ‘CLEAR’• Next generationmultiformulation

platform• Overnight nasal decongestant• Class 1product– regulatory process

commencing• Design beingfinalised andproduction

scopingunderway• TARGET RELEASE – DECEMBER 2016

MUTE• Inmarket• Resolves snoring• Improves sleep quality• Adjuncttoexistingsleep therapies


S L E E P A P N E A – U S $ 3 2 B I L L I O N O P P O R T U N I T Y


W I T H A B I L L I O N D O L L A R P R O B L E M


© RHINOMED LTD 2015 COMMERICAL IN CONFIDENCE

M U T E – A N A D J U N C T T O E X I S T I N G O S A T H E R A P I E S

• Proofofcompliance isincreasingly required byinsurersbefore reimbursement

• RHINOMED nasal stentlowersnasal resistance

• Being increasingly recommended bySleepSpecialists, SleepTechnicians andENT’sasanadjunct

therapy toMandibular AdvancementDevices andLowAHIPatients toresolve compliance issues

• Working closelywithsleep specialists tobeginscopingtrial

Locationof anteriorcoronalsliceLocationof posterior

coronalslice


I N P E A P – A N E W F R O N T L I N E S L E E P A P N E A T H E R A P Y

• PatentedINPEAPtechnology• Targeting70%ofOSApatientswith

moderateOSA(AHI14-29)• Lowinvasive• Welltolerated• Nasalstentingcoupledwithnasally

deliveredEPAP• TrialunderwayatMonash LungandSleep

Dept.Monash Health

IntranasalPositiveExpiratoryAirwayPressure(INPEAP)



D R U G D E L I V E R Y – P R O O F O F C O N C E P T

37MILLION AMERICANSSUFFERFROMMIGRAINE

<25%ARESATISFIEDWITHTHEIREXISTINGTHERAPY

US$1.6BILLION - WORLDWIDE SALESOFIMITREX

EFFICACYANDSAFETY ESTABLISHED

. 7,026,000SUMATRIPANPRESCRIPTIONS

WILLSEEKTOPARTNER THISPROGRAM


S U M M A R Y

• Compellingtechnologyinagrowingglobalmarket

• Businessisrapidlyexpandingrevenuebasethroughglobaldistributionfootprint

• Keyfocusisexpansionin:

• USAandCanada

• UK

• Aust/NZbase

• NearTermnewflow– moredistributionagreements,SleepApneaTrialresultsexpected

• Cashonhand~AU$4.0million

• Compellinginvestmentcomparator– BreatheRightStrips– purchasedbyGSK- US$566min2007


MICHAEL JOHNSON, CEOe. [email protected]

t. +61 3 8416 0900w. rhinomed.global

changing the way the world breathes€¦ · mr ron dewhurst - chairman mr michael johnson – ceo...

Documents